MA-VERACODE
21.4.2022 17:52:05 CEST | Business Wire | Press release
Veracode , a leading global provider of application security testing (AST) solutions, today announced it has been positioned as a Leader for the ninth consecutive time in the 2022 Gartner Inc. Magic Quadrant for Application Security Testing1 . The company is the only vendor recognized as a Leader every single year since the report was first published.
“Since Veracode launched in 2006, we have played a significant role in shaping the application security market,” said Sam King, Chief Executive Officer at Veracode. “To be recognized as a Leader every single year, in our opinion, is a validation of our rich heritage, continued innovation, and strong vision for the future of software security and development. With cybersecurity taking center stage for enterprises across all industries, we’re proud to be a trusted partner for our customers, enabling them to bring development and security teams together to build and deliver secure software at the speed that business demands.”
According to Gartner, Veracode is recognized for its completeness of vision and ability to execute in the AST market. The company has also been identified in Gartner Peer Insights™ as a Customers’ Choice for Application Security Testing 2 , which is based on feedback and ratings from independent customer reviews.
Brian Roche, Chief Product Officer at Veracode, said, “The rapid acceleration of digital transformation, combined with increased software supply chain complexity and new cybersecurity regulations, means software security has never been more vital. Over the past year, we have focused heavily on geographical expansion with our European Region instance, and delivered new technologies, such as API Scanning, that address some of our customers’ biggest pain points. Our own platform evolution initiatives give us a deep understanding and appreciation for the challenges many of our customers face in their own digital transformation journeys, improving our capacity to function as a trusted advisor.”
Veracode’s comprehensive platform offers multiple testing types and integrates into popular development tools through a frictionless interface, providing a 360-degree view of application security posture. The company credits its position in the report to a laser focus on the transformation of its platform, launch of API Scanning, authentication management in dynamic analysis, and its static analysis and software composition analysis (SCA) capabilities Veracode’s SCA product uses natural language processing and machine learning to accurately identify vulnerabilities from multiple sources in open-source libraries. Through this proprietary process, the Veracode solution has identified hundreds of previously undetected vulnerabilities in open-source libraries in the last year alone.
In 2021, Veracode launched the Veracode European Region instance to support EU data residency requirements. The underlying platform has been leveraged to underpin Veracode’s much-anticipated FedRAMP instance, which will be introduced in the coming months.
“It’s a truly exciting time for Veracode. We have just announced a significant growth investment from TA Associates with a $2.5 billion valuation—a major milestone in our 16-year history—and look forward to a year of continued innovation and accelerating growth. We remain tirelessly committed to our mission of securing the software that powers our customers’ businesses, and our continued position as a Leader is, in our opinion, a testament to the passion and dedication of our team around the world,” King added.
To download a complimentary copy of the full 2022 Gartner Magic Quadrant Report, visit: https://info.veracode.com/2022-gartner-mq-gated.html
To learn more about application security from Veracode, please visit: https://www.veracode.com/products
1
Gartner, “Magic Quadrant for Application Security Testing” by Dale Gardner, Mark Horvath, Dionisio Zumerle, 18 April 2022.
2
Gartner, “Peer Insights ‘Voice of the Customer’: Application Security Testing” by Peer Contributors, 27 October 2021.
Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
Gartner and Peer Insights are trademarks of Gartner, Inc. and/or its affiliates. All rights reserved. Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences, and should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.
Gartner Peer Insights Customers’ Choice constitute the subjective opinions of individual end-user reviews, ratings, and data applied against a documented methodology; they neither represent the views of, nor constitute an endorsement by, Gartner or its affiliates.
Gartner and Magic Quadrant are registered trademarks of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved
About Veracode
Veracode is a leading AppSec partner for creating secure software, reducing the risk of security breach, and increasing security and development teams’ productivity. As a result, companies using Veracode can move their business, and the world, forward. With its combination of process automation, integrations, speed, and responsiveness, Veracode helps companies get accurate and reliable results to focus their efforts on fixing, not just finding, potential vulnerabilities. Learn more at www.veracode.com , on the Veracode blog and on Twitter .
Copyright © 2022 Veracode, Inc. All rights reserved. All other brand names, product names, or trademarks belong to their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220421005866/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
